In a clinical survey on ovarian cancer patients, dose-limiting toxicity did not occur even at high doses of MV-NIS [69] and also Russell et al. have reported that the mild toxicity of the MV-NIS-based therapy approach was eliminated within a week [60]. Here, SLC5A5 is linked to ovarian cancer.